Volume 6.29 | Jul 31 - Cord Blood News

Cord Blood News 6.29 July 31, 2014

TOP STORY

Are Serum-Free and Xeno-Free Culture Conditions Ideal for Large Scale Clinical Grade Expansion of Wharton’s Jelly Derived Mesenchymal Stem Cells? A Comparative Study
Investigators established a complete xeno-free, serum-free culture condition for isolation, expansion and characterization of Wharton’s Jelly mesenchymal stromal/stem cells, to eliminate the use of animal components right from initiation of explant culture to clinical scale expansion and cryopreservation. [Stem Cell Res Ther] Abstract | Full Article

Technical Bulletin: Assays For Cord Blood

PUBLICATIONS (Ranked by impact factor of the journal)

Mycophenolate Mofetil versus Methotrexate for Prevention of Graft-versus-Host Disease in People Receiving Allogeneic Hematopoietic Stem Cell Transplantation
Investigators assessed the effect of mycophenolate mofetil versus methotrexate for prevention of acute graft-versus-host disease in people undergoing allogeneic hematopoietic stem cell transplantation. [Cochrane Database Syst Rev] Abstract

Immune Regulatory Properties of CD117^pos Amniotic Fluid Stem Cells Vary According to Gestational Age
Researchers analyzed the in vitro immunological properties of amniotic fluid stem cells from different gestational age in coculture with T, B and NK cells. [Stem Cells Dev] Abstract

In Vitro Immunomodulatory Effects of Microencapsulated Umbilical Cord Wharton Jelly-Derived Mesenchymal Stem Cells in Primary Sjögren’s Syndrome
Scientists aimed to assess the in vitro effects of IFN-γ-pretreated microencapsulated-human umbilical cord Wharton jelly-derived mesenchymal stem cells on T cells of primary Sjögren’s syndrome. [Rheumatology] Abstract

The Effects of CAMPATH-1H on Cell Viability Do Not Correlate to the CD52 Density on the Cell Surface
Scientists analyzed CD52 expression and the effects of CAMPATH-1H on fresh or frozen, resting or activated, peripheral blood mononuclear cells and cord blood mononuclear cells. [PLoS One] Full Article

Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources
Researchers compared total hospital length of stay in the first 100 days after hematopoietic cell transplantation (HCT) in 1577 patients with acute leukemia in remission receiving umbilical cord blood, matched unrelated donor or mismatched unrelated donors HCT. [Biol Blood Marrow Transplant] Abstract

Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Non-Follicular Indolent Lymphoma
Scientists describe a multicenter, retrospective cohort study of patients with biopsy-proven indolent B-cell non-follicular non-Hodgkin lymphoma, and simultaneous or subsequent biopsy-proven aggressive histology transformation who were treated with allogeneic and autologous stem cell transplantation. [Biol Blood Marrow Transplant] Abstract

HHV-6 Reactivation before Engraftment Is Strongly Predictive of Graft Failure after Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults
Investigators aimed to determine new factors associated with engraftment and single-unit predominance after double umbilical cord blood allogeneic stem-cell transplant. [Exp Hematol] Abstract

Free Poster: Quick Reference for Mouse Immune Cell Frequencies and Percentages

REVIEWS

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults
The authors highlight available evidence in treatment of older adults with acute myeloid leukemia or myelodysplastic syndromes and unanswered clinical questions for older adults with these diseases. [J Clin Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Stem Cells and Regenerative Medicine Asia Congress 2014

INDUSTRY NEWS

Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders
Fate Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug Application (IND) for the clinical development of PROHEMA^® in pediatric patients undergoing hematopoietic stem cell transplantation for the treatment of inherited metabolic disorders. [Fate Therapeutics, Inc.] Press Release

Innate Pharma SA Announces Completion of Target Enrollment in the Phase II EffiKIR Trial
Innate Pharma SA announced completion of target enrollment in the EffiKIR trial with 150 patients randomized. EffiKIR is a double-blind placebo-controlled randomized Phase II trial of lirilumab as maintenance treatment in elderly patients with acute myeloid leukemia in first complete remission. [Innate Pharma SA] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW 2014 Till & McCulloch Meetings
October 27-29, 2014
Ottawa, Canada

Visit our events page to see a complete list of events in the cord blood community.

JOB OPPORTUNITIES

NEW Postdoctoral Positions – Reprogramming and Genetic Engineering Technologies to Develop New Models of Hematopoiesis and Hematopoietic Disorders (Icahn School of Medicine)

Hematopoietic Stem Cell Scientist – Human Genetic Disorders (Editas Medicine)

Biologist or Immunologist – Hematology and Stem Cell Transplantation (University Hospital Aachen)

Postdoctoral Researcher – Hematopoietic Stem Cell Maintenance (Baylor College of Medicine)

Postdoctoral Fellow – Fetal Imprinting and Establishment of the Methylome in Cord Tissue and Placenta (University of Freiburg)

Hematology Investigator (Case Western Reserve University)

Cord Tissue Processing Technician (Cord Blood Registry)

Postdoctoral Position – Hematopoietic Stem Cell Research (UT Southwestern Medical Center at Dallas)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here

Learn more about Cord Blood News: Archives | Events | Contact Us